REIG JOFRE and LEO PHARMA join forces to improve access to an innovative psoriasis treatment in Primary Care
Both companies collaborate to expand access to the leading treatment in Europe for mild to moderate psoriasis, bringing effective solutions to more patients and healthcare professionals across Spain.
REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the Spanish Stock Exchange’s continuous market, has signed a commercial agreement with LEO Pharma, a pharmaceutical company specializing in medical dermatology and thrombosis. The partnership aims to strengthen the promotion of LEO Pharma’s innovative treatment for mild to moderate psoriasis within the scope of Primary Care in Spain.
Psoriasis is one of the most prevalent dermatological conditions, and Family and Community Medicine specialists play a key role in its diagnosis and management. Within this context, the collaboration between REIG JOFRE with a strong track record in the pharmaceutical sector and a commercial team deeply rooted in Primary Care and LEO Pharma will help extend the treatment’s reach, improving patient access and enhancing support for healthcare professionals.
In the topical treatment market for psoriasis, this therapy stands out as the undisputed leader both in Spain and across Europe. Endorsed by clinical guidelines from the main scientific societies (SEMFyC, SEMERGEN, and SEMG), it combines calcipotriol, a vitamin D analogue, with betamethasone dipropionate. This unique formulation significantly improves anti-psoriatic response and has been recognized by Farmaindustria as an incremental innovation, thanks to its advanced foam-based pharmaceutical formulation. Notably, it is the only dermatology drug within Spain’s National Health System to have received this distinction, underscoring its therapeutic relevance and strong acceptance among dermatology specialists.
Beyond promoting the treatment, both pharmaceutical groups will continue to work closely with leading scientific societies in Primary Care. They share a firm commitment to advancing education in dermatology, supporting initiatives focused on early diagnosis and improved detection of skin diseases, and promoting the dissemination of new scientific evidence that fosters progress in this field.
This agreement marks a significant milestone in positioning REIG JOFRE and LEO Pharma as key players in medical dermatology in Spain. LEO Pharma, a leader in topical psoriasis treatment, demonstrates its trust in REIG JOFRE as a strategic partner, acknowledging its robust expertise in dermatology, deep understanding of the healthcare landscape, and extensive presence in Primary Care. This collaboration ensures that healthcare professionals receive the support, proximity, and information needed to provide the best possible care to their patients.
Through this alliance, REIG JOFRE and LEO Pharma strengthen their shared commitment to universalizing science that matters, making scientifically validated and effective therapeutic solutions accessible to as many patients as possible. Through innovation, excellence, and ongoing support for healthcare professionals, both companies move forward with their shared purpose of improving quality of life and ensuring equitable access to essential health treatments.